- Molecular NameProbenecid
- SynonymProbenecid Acid; probenicid
- Weight285.364
- Drugbank_IDDB01032
- ACS_NO57-66-9
- Show 3D model
- LogP (experiment)3.21
- LogP (predicted, AB/LogP v2.0)2.93
- pka3.4
- LogD (pH=7, predicted)-0.39
- Solubility (experiment)0.0271 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.6
- LogSw (predicted, AB/LogsW2.0)0.96
- Sw (mg/ml) (predicted, ACD/Labs)0.16
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds7
- TPSA83.06
- StatusFDA approved
- AdministrationN/A
- PharmacologyA uricosuric drug that increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia.
- Absorption_value100.0
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability80.0
- Protein binding90.0
- Volume of distribution (VD)0.14~ 0.2 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmRapid and extensive; hydroxylated to active metabolites and probenecid monacylglucuronide in the liver.
- Half life4~17 h (dose-dependent)
- Excretionrenal (77-88%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityHeadaches, dizziness, dermatitis, pruritus, anorexia, nausea, GI distress, vomiting, sore gums, Urinary frequency, hematuria, renal colic, nephrotic syndrome, anemia, hemolytic anemia (possibly related to G-6-PD deficiency), aplastic anemia, hepatic necrosis, hypersensitivity reactions, anaphylaxis, fever, flushing, exacerbation of gout, uric acid stones, costovertebral pain.
- LD50 (rat)N/A
- LD50 (mouse)N/A